FIGURE 1.

Suggested algorithm for the management of IPF and PPF. *Subsidized prescribing criteria will vary depending on jurisdiction. Observation of fibrotic disease progression in an ILD other than IPF should prompt review of the disease specific management approach, consideration of re‐evaluation of the diagnosis at an ILD‐MDM and consideration of nintedanib should it be accessible. Enrolment in clinical trials should be considered for all patients with IPF and PPF. Alongside pharmacologic therapies, all ILD patients should be considered for supportive therapies as well as lung transplantation and palliative care where relevant. ILD, interstitial lung disease; MDM, multi‐disciplinary meeting; PPF, progressive pulmonary fibrosis.